Aytu BioPharma (AYTU)
Commercializer of prescription medicines for depression, ADHD, and pediatric conditions.
Something off on this page? Send us feedback.
Sells prescription medicines for adult depression, ADHD, and pediatric conditions through its commercial organization and third-party channels. The business is a single U.S.-focused segment shifting attention toward licensed EXXUA while its ADHD portfolio remains its main revenue base.
Commercializes prescription medicines for central-nervous-system conditions, centering on EXXUA for adult major depressive disorder and the ADHD products Adzenys XR-ODT and Cotempla XR-ODT. A smaller pediatric portfolio includes Karbinal ER and Poly-Vi-Flor and Tri-Vi-Flor. Products reach U.S. customers through an internal commercial organization, wholesalers, distributors, pharmacies, and RxConnect network pharmacies; the ADHD products also have partners pursuing approval and commercialization in Canada, Israel, and the Palestinian Authority.
Operates as one reportable prescription-pharmaceutical segment after divesting Consumer Health and suspending clinical-development programs. Commercial activity increasingly focuses on licensed EXXUA, while legacy ADHD products remain the primary revenue base and face generic competition. Revenue depends on third-party manufacturing and distribution, controlled-substance rules for the ADHD portfolio, payor access, and the EXXUA licensing agreement.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $26.3M · Total debt $1.9M · Total assets $105.0M · Shareholders' equity $35.3M
- Revenue
- $16.1M
- Operating income
- −$777.0K
- Net income
- −$15.0K
No dividends on record.
| Institutions | 35.74% | 3.84M shares | |
|---|---|---|---|
| 36 holders · as of Jun 30, 2026 | |||
| Insiders | 15.19% | 1.63M shares | |
| 9 holders · as of Jul 30, 2026 | |||
| Other | 49.07% | 5.27M shares | |
| remainder | |||
10.73M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Nantahala Capital Management, LLCInstitution | 10.13% | 1.09M | as of Jun 30, 2026 |
Lytton Laurence W.Insider | 9.98% | 1.07M | filed Feb 17, 2026 |
Stonepine Capital Management, LLCInstitution | 8.51% | 912,921 | as of Jun 30, 2026 |
Awm Investment Company, Inc.Institution | 5.77% | 619,574 | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 2.43% | 261,146 | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Teva (ADR)
Immediate generic pressure on the ADHD XR-ODT franchise.
- Takeda (ADR)
Branded ADHD and MDD alternatives across both commercial priorities.
- Axsome Therapeutics
Fast-growing branded oral MDD alternative with broad payer reach.
- Johnson & Johnson
Established long-acting methylphenidate brand for ADHD prescribers.
- Amneal Pharmaceuticals
Low-cost generic extended-release stimulant pressure in ADHD.
- AbbVie
Adjunctive MDD therapy for antidepressant partial responders.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Aytu BioPharma | $2.13 | −4.48% | $23.9M | — | 8.5 | 0.4 | +6.4% |
| Teva (ADR) | $39.61 | +0.23% | $46.03B | 65.9 | 14.1 | 2.7 | −0.8% |
| Takeda (ADR) | $18.92 | −0.18% | $60.30B | 52.9 | 60.2 | 2.0 | +4.2% |
| Axsome Therapeutics | $199.79 | −1.63% | $10.45B | — | 1,192.0 | 13.5 | +44.2% |
| Johnson & Johnson | $270.95 | +0.65% | $648.72B | 31.2 | 22.8 | 6.6 | +6.6% |
| Amneal Pharmaceuticals | $19.36 | −0.71% | $6.23B | 40.0 | 19.4 | 2.0 | +9.9% |
| AbbVie | $267.13 | +0.72% | $468.77B | 74.8 | 17.6 | 7.3 | +10.2% |
| Median | 52.9 | 21.1 | 4.6 | +8.2% |